Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines
Jee Hye Kang, Jeffrey A. Bluestone, Arabella Young
Trends in Immunology (2021) Vol. 42, Iss. 4, pp. 293-311
Closed Access | Times Cited: 86

Showing 26-50 of 86 citing articles:

How to diagnose and manage neurological toxicities of immune checkpoint inhibitors: an update
Alberto Vogrig, Sergio Muñiz‐Castrillo, Antonio Farina, et al.
Journal of Neurology (2021) Vol. 269, Iss. 3, pp. 1701-1714
Closed Access | Times Cited: 29
Immune Checkpoint Inhibitor-Associated Cardiotoxicity in Solid Tumors: Real-World Incidence, Risk Factors, and Prognostic Analysis
Xue Chen, Aimin Jiang, Rui Zhang, et al.
Frontiers in Cardiovascular Medicine (2022) Vol. 9
Open Access | Times Cited: 19
Progress in nanoparticle-based regulation of immune cells
Ya-Nan Fan, Gui Zhao, Yue Zhang, et al.
Medical Review (2023) Vol. 3, Iss. 2, pp. 152-179
Open Access | Times Cited: 12
Cutaneous Adverse Reactions of Immunotherapy in Patients with Advanced Melanoma
Vasiliki Nikolaou, Antonios Tsimpidakis, Alexander J. Stratigos
Cancers (2023) Vol. 15, Iss. 7, pp. 2084-2084
Open Access | Times Cited: 11
Prognostic impact of LILRB4 expression on tumor‐infiltrating cells in resected non‐small cell lung cancer
Sakiko Kumata, Hirotsugu Notsuda, Mei‐Tzu Su, et al.
Thoracic Cancer (2023) Vol. 14, Iss. 21, pp. 2057-2068
Open Access | Times Cited: 11
Cytokine and soluble programmed death-ligand 1 levels in serum and plasma of cancer patients treated with immunotherapy: Preanalytical and analytical considerations
Elia Cappelletto, Laura Tiozzo Fasiolo, Valentina Salizzato, et al.
The International Journal of Biological Markers (2024) Vol. 39, Iss. 1, pp. 9-22
Open Access | Times Cited: 4
Shifting the paradigm: engaging multicellular networks for cancer therapy
Joyce Hu, Paolo A. Ascierto, Alessandra Cesano, et al.
Journal of Translational Medicine (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 4
The Current and Future of Biomarkers of Immune Related Adverse Events
William Bracamonte‐Baran, Sang T. Kim
Rheumatic Disease Clinics of North America (2024) Vol. 50, Iss. 2, pp. 201-227
Closed Access | Times Cited: 4
Elevated IL-6 and Tumor Necrosis Factor-α in Immune Checkpoint Inhibitor Myocarditis
Abdelrahman Ali, Rebecca L. Caldwell, Gaspar Pina, et al.
Diseases (2024) Vol. 12, Iss. 5, pp. 88-88
Open Access | Times Cited: 4
Dual efficacy of tocilizumab in managing PD-1 inhibitors-induced myocardial inflammatory injury and suppressing tumor growth with PD-1 inhibitors: a preclinical study
Yanxin Chen, Yuxi Luo, Yunwei Liu, et al.
Cancer Immunology Immunotherapy (2025) Vol. 74, Iss. 2
Open Access
Prediction, prevention, and precision treatment of immune checkpoint inhibitor neurological toxicity using autoantibodies, cytokines, and microbiota
Alberto Vogrig, Marta Dentoni, Irene Florean, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
The Current and Future of Biomarkers of Immune Related Adverse Events
William Bracamonte‐Baran, Sang T. Kim
Immunology and Allergy Clinics of North America (2025) Vol. 45, Iss. 2, pp. 223-249
Closed Access
Cancer Cachexia-Related Monocytic MDSCs Impair T-Cell Negative Selection and Predict Immune-Related Adverse Events
Wěi Li, Ya-Qin Sun, Jianhua Ren, et al.
(2025)
Closed Access
Immunotherapy Combined With Radiation Therapy for Genitourinary Malignancies
Jacob Ukleja, Erika Kusaka, David T. Miyamoto
Frontiers in Oncology (2021) Vol. 11
Open Access | Times Cited: 26
Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
Sophia Bylsma, Karen Yun, Sandip Pravin Patel, et al.
Current Treatment Options in Oncology (2022) Vol. 23, Iss. 9, pp. 1153-1168
Open Access | Times Cited: 17
Synergy and Coordination Between Biomimetic Nanoparticles and Biological Cells/Tissues/Organs/Systems: Applications in Nanomedicine and Prospect
Eliasu Issaka, Mary Adumo Wariboko, Enock Adjei Agyekum
Deleted Journal (2023) Vol. 2, Iss. 1, pp. 1-33
Open Access | Times Cited: 10
Checkpoint Inhibitor-Induced Colitis: From Pathogenesis to Management
Maria Terrin, Giulia Migliorisi, Arianna Dal Buono, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11504-11504
Open Access | Times Cited: 10
Impact of Radiation on Exosomes in Regulating Tumor Immune Microenvironment
Silai Yu, Shanshan Jiang, Yue Zhou, et al.
Advances in Radiation Oncology (2024) Vol. 9, Iss. 8, pp. 101549-101549
Open Access | Times Cited: 3
Steroid-Refractory Myocarditis Induced by Immune Checkpoint Inhibitor Responded to Infliximab: Report of Two Cases and Literature Review
Sihan Tan, Qi Chang, Hao Zeng, et al.
Cardiovascular Toxicology (2024) Vol. 24, Iss. 11, pp. 1174-1191
Open Access | Times Cited: 3
Adverse Cardiovascular Complications following prescription of programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors: a propensity-score matched Cohort Study with competing risk analysis
Jiandong Zhou, Sharen Lee, Ishan Lakhani, et al.
Cardio-Oncology (2022) Vol. 8, Iss. 1
Open Access | Times Cited: 15
Predictive mutation signature of immunotherapy benefits in NSCLC based on machine learning algorithms
Zhichao Liu, Lin Guo, Zeping Yan, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 15
Predicting the immune microenvironment and prognosis with a anoikis - related signature in breast cancer
Xiuqing Lu, Qi Yuan, Chao Zhang, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 7
Sequential severe immune-related adverse events induced by PD-1 inhibitor: a case report and literature review
Jinxiong Xia, Yingmei Wen, Mengxia Xiao, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Biomarkers associated with immune-related adverse events induced by immune checkpoint inhibitors
Anjie Guo, Qing-Yuan Deng, Pan Dong, et al.
World Journal of Clinical Oncology (2024) Vol. 15, Iss. 8, pp. 1002-1020
Open Access | Times Cited: 2
Cytokine release syndrome caused by immune checkpoint inhibitors: a case report and literature review
Xiuping Zhang, You Yang, Pengfei Zhang, et al.
Future Science OA (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 2

Scroll to top